Levosimendan Fmk

Levosimendan, the active ingredient in Levosimendan Fmk, is a calcium sensitizer presented as a intravenous solution for intravenous use. It treats acute decompensated heart failure in adult patients. GNH USA supplies Levosimendan Fmk as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is a calcium sensitizer used in the management of acute heart failure.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. Severe left ventricular dysfunction: enhances contractility during hospitalisation. Post‑cardiac surgery low cardiac output: supports hemodynamics when conventional therapy is insufficient.

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure, especially after infusion start. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate during infusion. - Arrhythmias: premature beats or mild rhythm disturbances.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure fall requiring intervention. - Ventricular arrhythmias: potentially life‑threatening rhythm disorders. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary flow. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema worsening: fluid accumulation despite therapy.

When using Levosimendan, clinicians should consider several safety measures. - Blood pressure monitoring: watch for hypotension during and after infusion. - Cardiac rhythm surveillance: detect arrhythmias early. - Renal function assessment: adjust therapy in severe impairment. - Hepatic function assessment: caution in significant liver disease. - Concomitant vasodilators: avoid excessive vasodilation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Potent vasodilators (e.g., nitroglycerin, sodium nitroprusside): risk of severe hypotension. - Strong CYP450 inhibitors: may increase plasma levels. - Drugs that prolong QT interval: heightened arrhythmia risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic response. - Calcium channel blockers: potential additive cardiac effects. - Diuretics: monitor electrolytes and volume status. - ACE inhibitors or ARBs: additive blood pressure lowering. - Digoxin: observe for changes in serum concentration.